Q1 FY2027 · ended Aug 31, 2026 · Revenue $80.92M, +6.9% YoY · Filed Oct 8, 2026
AngioDynamics, Inc. (ANGO) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q1 of fiscal 2027, the quarter ended Aug 31, 2026, it reported revenue of $80.9 million and a net loss of $7.1 million. Free cash flow was -$15.7 million. As of Aug 31, 2026 it held $34.0 million in cash and investments and $7.3 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- ANGO (Nasdaq)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Latham, NY
- SEC filer status
- Accelerated filer
- SEC CIK
- 1275187
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Aug 31, 2026 |
Q4 FY2026 May 31, 2026 |
Q3 FY2026 Feb 28, 2026 |
Q2 FY2026 Nov 30, 2025 |
Q1 FY2026 Aug 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $80.9M | $86.6M | $78.4M | $79.4M | $75.7M |
| Operating income | -$7.3M | -$10.2M | -$13.0M | -$6.1M | -$10.7M |
| Net income | -$7.1M | -$11.4M | -$8.1M | -$6.3M | -$10.9M |
| Diluted EPS | -$0.17 | -$0.27 | -$0.19 | -$0.15 | -$0.26 |
| Operating cash flow | -$15.3M | $17.5M | -$3.1M | $4.7M | -$15.9M |
| Free cash flow | -$15.7M | $17.0M | -$4.1M | $4.2M | -$16.6M |
| Total assets | $241.9M | $267.2M | $260.7M | $269.7M | $265.6M |
| Total liabilities | $78.0M | $96.3M | $87.3M | $93.3M | $86.8M |
| Stockholders' equity | $164.0M | $170.8M | $173.4M | $176.3M | $178.9M |
| Cash and investments | $34.0M | $53.9M | $37.8M | $41.6M | $38.8M |
| Total debt | $7.3M | $11.0M | $7.9M | $8.3M | $6.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 8, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Oct 8, 2026 | Oct 2, 2026 |
| 10-K/A | Amended annual report | Sep 29, 2026 | May 31, 2026 |
| 10-K/A | Amended annual report | Sep 29, 2026 | May 31, 2026 |
| 10-K | Annual report | Jul 14, 2026 | May 31, 2026 |
All 1000 AngioDynamics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.